4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists
A series of 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2-naphthalenecarboxamide dopamine (DA) D3 receptor agonists has been identified. These compounds were found to be selective for DA D3 over D2 receptors and were shown to be partial to full agonists as measured by stimulation of mitogenesis in D3-transfected CHO p-5 cells.
References (12)
- et al.
Eur. J. Pharmacol.
(1993) - et al.
Nature
(1990) - et al.
Chem. Abstr.
(1993) - et al.
J. Pharmacol. Exp. Ther.
(1995) Drugs of the Future
(1991)
Cited by (16)
Evaluation of N-phenyl homopiperazine analogs as potential dopamine D <inf>3</inf> receptor selective ligands
2013, Bioorganic and Medicinal ChemistryCitation Excerpt :Examples include BP 897, NGB 2904, and the structural congeners 1–5 (Fig. 1).18–20 A common structural feature of these conformationally-flexible benzamides is the N-arylpiperazine ring and the 4-carbon spacer group separating the benzamide and the piperazine moieties.18,21–25 The lipophilic residue on the arylamide moiety permits diverse modifications including aryl, biphenyl, heteroaryl, or cycloalkyl substituents.
Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D <inf>3</inf> receptor ligands
2005, Bioorganic and Medicinal ChemistryConformationally-flexible benzamide analogues as dopamine D<inf>3</inf> and σ<inf>2</inf> receptor ligands
2004, Bioorganic and Medicinal Chemistry LettersPhenyloxazoles and phenylthiazoles as benzamide bioisosteres: Synthesis and dopamine receptor binding profiles
2000, Bioorganic and Medicinal Chemistry LettersPhenylpiperazine derivatives with strong affinity for 5HT(1A), D(2A) and D<inf>3</inf> receptors
1998, Bioorganic and Medicinal Chemistry Letters